Rolul scorurilor non-invazive în diagnosticul fibrozei hepatice la persoanele cu diabet zaharat tip 2
Open Access
- 18 November 2024
- journal article
- Published by AO Economie, Management si Psihologie in Medicina in Public Health, Economy and Management in Medicine
- No. 5(102),p. 71-75
Abstract
Liver fibrosis represents one of the most pressing problems of steatotic liver disease, as it contributes to disease progression and increases the risk of mortality. Early detection of people with type 2 diabetes and liver fibrosis is essential in disease management, to avoid complications. The study is based on the review of the research articles published during the period 01.01.2007-30.05.2024, in the databases PubMed, ScienceDirect, and Google Academic. From the total number of 280 articles, 27 relevant articles were selected. Non-invasive scores are algorithms that incorporate different clinical variables and biomarkers, increasing the sensitivity and specificity of identifying liver fibrosis. The most commonly used scores are APRI, BARD, NFS, FibroTest, and FIB-4. Recent studies demonstrated that these scores have been validated and can be applied in clinical practice. However, the FIB-4 score exceeds the accuracy of other non-invasive scores and has been recommended by several international societies as a screening method for liver fibrosis in people with type 2 diabetes. Noninvasive scores represent promising, useful, and cost-effective diagnostic methods for the diagnosis of liver fibrosis in people with type 2 diabetes. They provide an assessment of prognosis and the development of effective personalized management strategies, eliminating the risks associated with liver biopsy.Keywords
This publication has 27 references indexed in Scilit:
- A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetesJournal of Hepatology, 2022
- Low accuracy of FIB-4 test to identify people with diabetes at low risk of advanced fibrosisJournal of Hepatology, 2022
- Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver diseaseScientific Reports, 2022
- Non-invasive diagnosis of nonalcoholic fatty liver disease in patients with type 2 diabetesJournal of Diabetes and its Complications, 2021
- Embedding assessment of liver fibrosis into routine diabetic review in primary careJHEP Reports, 2021
- Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care SettingHepatology Communications, 2020
- Clinical utility of noninvasive scores in assessing advanced hepatic fibrosis in patients with type 2 diabetes mellitus: a study in biopsy-proven non-alcoholic fatty liver diseaseActa Diabetologica, 2020
- A Pragmatic Approach Identifies a High Rate of Nonalcoholic Fatty Liver Disease With Advanced Fibrosis in Diabetes Clinics and At‐Risk Populations in Primary CareHepatology Communications, 2018
- Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD FibrosisAmerican Journal of Gastroenterology, 2017
- The NAFLD fibrosis scoreHepatology, 2007